Adrian Adams's Net Worth
$3.88 Million
Who is Adrian Adams?
Adrian Adams has an estimated net worth of $3.88 Million. This is based on reported shares across multiple companies, which include NEUROLOGIX INC/DE, NEUROCRINE BIOSCIENCES INC, IMPEL PHARMACEUTICALS INC, Akebia Therapeutics, Inc., Aralez Pharmaceuticals Inc., ACELRX PHARMACEUTICALS INC, AUXILIUM PHARMACEUTICALS INC, AMYLIN PHARMACEUTICALS INC, POZEN INC /NC, SEPRACOR INC /DE/, INSPIRE PHARMACEUTICALS INC, and KOS PHARMACEUTICALS INC.
SEC CIK
Adrian Adams's CIK is 0001248144
Past Insider Trading and Trends
2011 was Adrian Adams's most active year for acquiring shares with 12 total transactions. Adrian Adams's most active month to acquire stocks was the month of May. 2005 was Adrian Adams's most active year for disposing of shares, totalling 19 transactions. Adrian Adams's most active month to dispose stocks was the month of November. 2007 saw Adrian Adams paying a total of $30,918,750.00 for 625,000 shares, this is the most they've acquired in one year. In 2015 Adrian Adams cashed out on 1,013,278 shares for a total of $33,448,110.02, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
NEUROLOGIX INC/DE No price found
CEO, CHAIRMAN OF THE BOARD
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
NEUROCRINE BIOSCIENCES INC (NBIX) Snapshot price: $136.33
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
IMPEL PHARMACEUTICALS INC (IMPL) Snapshot price: $0.05
COB, CEO and President
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 26
| |||
Form 4
|
∞
| 20K |
$13.99 | $279,789.58 | 20K |
Aug 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Akebia Therapeutics, Inc. (AKBA) Snapshot price: $1.65
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +22.26% | 30K |
—
|
—
| 164.8K |
Jun 6
| |||
Form 4
| +28.63% | 30K |
—
|
—
| 134.8K |
Jun 6
| |||
Form 4
| +15.04% | 13.7K |
—
|
—
| 104.8K |
Jun 8
| |||
Form 4
| +17.70% | 13.7K |
—
|
—
| 91.1K |
Jun 2
| |||
Form 4
| +21.51% | 13.7K |
—
|
—
| 77.4K |
Jun 5
| |||
Form 4
| +364.96% | 50K |
$3.41 | $170,500.00 | 63.7K |
Nov 20
| |||
Form 4
|
∞
| 13.7K |
—
|
—
| 13.7K |
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aralez Pharmaceuticals Inc. No price found
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +6.12% | 218.38K |
—
|
—
| 3.79M |
May 11
| |||
Form 4
| +16.29% | 500K |
$2.46 | $1,230,950.00 | 3.57M |
Mar 15
| |||
Form 4
| +4.22% | 124.34K |
—
|
—
| 3.07M |
Mar 17
| |||
Form 4
|
∞
| 2.94M |
—
|
—
| 2.94M |
Feb 5
| |||
| No matching records found | |||||||||